Site Search

1. 191.
   AMP/assets/File/position-statements/2016/AMPcomments-genetictestresults-FDA-2015...

   S1525-1578(14)00245-1/fulltext#sec9 2 http://university.asco.org/motb 3 http://jmd.amjpathol.org/article/S1525-1578%2814%2900245-1/fulltext Page 3 of 4 guidelines and framework for interpretation and ... v17/n5/full/gim201530a.html 5 http://jmd.amjpathol.org/article/S1525-1578%2815%2900264-0/fulltext Page 4 of 4 into account their knowledge of the

   https://www.amp.org/AMP/assets/File/position-statements/2016/AMPcomments-genetic...
2. 192.
   AMP/assets/File/annualreports/AnnualReport_2018.pdf?pass=98

   Our international community grew by a remarkable 20% in 2018, and we now have members practicing in 51 countries. In 2018, we hosted ... UT.. . 2,201 2018. . . SAN ANTONIO, TX. . . 2,106 AMP MEMBERS BY DEGREE: PhD 875 (34.8%) MD 1074 (42.7%) Other 565 (22.5%) Recipients of the Jeffrey A. Kant Leadership Award gathered at the 2018 Annual Meeting & Expo. A

   https://www.amp.org/AMP/assets/File/annualreports/AnnualReport_2018.pdf?pass=98
3. 193.
   AMP/assets/File/position-statements/2015/AMPCommentsonCLFS-CY2016-FINAL.pdf?pass...

   approximately one-fifth or 20% of the cost of traditional Sanger sequencing. ... 81410 is 9 and totals 240 exons. 20% of 240 is 48 exons. This is approximately ... Minimum of 9 genes (240 exons). 240 times 20% = 48 48 divided by 21 = 2.28 Crosswalk to 81292 ... per genomic sequencing procedure and applying a 20% reduction to determine the crosswalk, we identified that

   https://www.amp.org/AMP/assets/File/position-statements/2015/AMPCommentsonCLFS-C...
4. 194.
   September2013

   For the full report, visit: http://www.journals.elsevierhealth.com/periodicals/jmdi/article/S1525-1578%2813%2900112-8/abstract Laboratory Practice Guidelines for Detecting and Reporting JAK2 ... visit: http://www.journals.elsevierhealth.com/periodicals/jmdi/article /S1525-1578%2813%2900131-1/abstract For information about submitting a manuscript to JMD,

   https://www.amp.org/AMP/assets/File/newsletter/September2013.pdf?pass=36
5. 195.
   Association of Molecular Pathology

   approximately one-fifth or 20% of the cost. • ... below),theminimumrequiredgenesfor81410is9andtotals240exons.20%of240is48exons.Thisisapproximately2timesthenumberofexonsfortheMLH1geneincode81292.Giventhisrelationshipwhichincludesthecostsavingsofperforminggenomicsequencing ... exons). 240 times 20% = 4848 divided by 21 ... and apply a 20% reduction to determine the

   https://www.amp.org/AMP/assets/File/position-statements/2015/2015CLFSMeeting-AMP...
6. 196.
   Annual Meeting Corporate Workshops - Association for Molecular Pathology

   derived FFPE samples, achieving 100% concordance with NGS and high reproducibility, ... metastatic Breast Cancer (mBC). Up to 40% of HR+ mBC patients on Aromatase Inhibitors ... Isolation Kit to deliver sensitivity of ≤0.1% for 11 ESR1 mutations located in the ligand ... increases fully reported tumor profiles by 16%, offering cost savings, efficiency, and reduced re

   https://www.amp.org/education/corporate-workshops/annual-meeting-corporate-works...
7. 197.
   FINAL: STAKEHOLDER SIGN ON, HR 3107 (D0839956).DOCX

   Advantage enrollment has nearly doubled in a decade. One-third (34%) of all Medicare beneficiaries — 22 million people — are enrolled ... plans, and nearly four out of five enrollees (79%) are in plans that require prior authorization for some ... to nearly half of all Medicare beneficiaries (about 47%) by 2029. Recognizing the need to protect a growing

   https://www.amp.org/AMP/assets/FINAL STAKEHOLDER SIGN ON HR 3107 090919.pdf?pass...
8. 198.
   AMP/assets/File/clinical-practice/0726_28-30_AMPcase-Chakraborty_reprint_HighRes...

   Met444LysLikely oncogenic26%MSH6NM_000179.3:c.3964G>Tp.Glu1322TerPathogenic21%PIK3CANM_006218.4:c.263G>Ap.Arg88GlnOncogenic21%Table 1. Tier 1 (clinically actionable) somatic variants identified by the paired tumor germline sequencing using the Oncomine Comprehensive Assay v3; VAF (variant allele fraction, ≥5 percent) is defined as the proportion of

   https://www.amp.org/AMP/assets/File/clinical-practice/0726_28-30_AMPcase-Chakrab...
9. 199.
   AMP/assets/File/education/case-studies/0419_26-28_AMPcase_reprint-LR.pdf?pass=23

   1 (long form) 45-55% bcr-3 (short form) 35-45% bcr-2 (variable form) 5-10% bcr-1 (long form) 45 to 55 percent bcr-3 (short form) 35 to 45 percent bcr-2 (variable form) 5 to 10 percent Fig. 1. The breakpoint of RARA occurs at intron 2, but the breakpoint of PML can occur at different locations, resulting in three different fusion transcripts termed bcr-1,

   https://www.amp.org/AMP/assets/File/education/case-studies/0419_26-28_AMPcase_re...
10. 200.
    AMP/assets/File/advocacy/ReducingHereditaryCancerAct_LOS_03_24_2022.pdf?pass=5

    Research shows that inherited genetic mutations play a major role in approximately 10% of cancers, including breast, ovarian, endometrial, prostate, pancreatic ... no reliable screening or early detection; more than 75% of affected women are diagnosed with advanced-stage disease (Stage III or IV).4 Up to 25% of ovarian cancers are attributable to an inherited

    https://www.amp.org/AMP/assets/File/advocacy/ReducingHereditaryCancerAct_LOS_03_...